UBS Group
MLTX icon

UBS Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

UBS Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-31,800
Closed -$1.81M – 9680
2023
Q3 		$1.81M Buy
+31,800
New +$1.76M ﹤0.01% 3533

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group's MLTX Position: Q2 2026 in Review

UBS Group increased its MoonLake Immunotherapeutics (MLTX) stake by 8,369% in Q2 2026, buying an estimated $5.88M and bringing the position to 328,522 shares worth $6.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3904.

UBS Group first reported a position in MLTX in Q2 2021 and has held it in 18 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • UBS Group held 328,522 shares of MoonLake Immunotherapeutics worth $6.4M as of Q2 2026.
  • UBS Group bought 324,643 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $5.88M.
  • MoonLake Immunotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3904 holding.
  • UBS Group first reported a position in MoonLake Immunotherapeutics in Q2 2021 and has held it in 18 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.